Gumaro Granados, MD
Family Medicine · Missouri City, TXNPI 1902244452
Payments from drug & device makers
Across 117 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$379
- Novo Nordisk$344
- Amgen$318
- GSK$266
- Boehringer Ingelheim$107
- Johnson & Johnson$106
- plus $652 from 18 others
What the payments were for
- Food & beverage$2,172100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $379 |
| Novo Nordisk | 25 | $344 |
| Amgen | 17 | $318 |
| GSK | 10 | $266 |
| Boehringer Ingelheim | 4 | $107 |
| Johnson & Johnson(2 entities) | 6 | $106 |
| AstraZeneca | 6 | $94 |
| Novartis | 4 | $74 |
| Bayer | 2 | $59 |
| Abbott | 3 | $57 |
| Exact Sciences | 2 | $53 |
| AbbVie | 3 | $49 |
| Merck | 4 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Inari Medical, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
| Althera Pharmaceuticals LLC | 1 | $7 |
How this compares
$2,172 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 107 | $147,158 |
| MounjaroTirzepatide | 81 | $90,744 |
| OzempicSemaglutide | 56 | $72,934 |
| TrulicityDulaglutide | 46 | $61,822 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $39,512 |
| TradjentaLinagliptin | 36 | $37,435 |
| Repatha SureclickEvolocumab | 37 | $26,496 |
| ProliaDenosumab | 15 | $25,501 |
| LinzessLinaclotide | 27 | $24,976 |
| EliquisApixaban | 14 | $23,451 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $22,477 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $17,016 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $16,240 |
| FarxigaDapagliflozin Propanediol | 15 | $16,060 |
| JanuviaSitagliptin Phosphate | 13 | $15,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $107 | $200,833157 claims |
| Lilly USA, LLCMounjaro, Trulicity | $379 | $152,566127 claims |
| Novo NordiskOzempic, Rybelsus | $344 | $87,72370 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Shingrix | $266 | $46,32392 claims |
| AmgenProlia | $318 | $25,50115 claims |
| AbbVieLinzess | $49 | $24,97627 claims |
| MerckJanuvia, Janumet Xr | $47 | $24,16026 claims |
| PfizerEliquis | $19 | $23,45114 claims |
| AstraZenecaFarxiga | $94 | $16,06015 claims |
| Johnson & JohnsonXarelto | $106 | $15,24715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Missouri City
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.